These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34109569)

  • 1. Smoking Cessation Pharmacotherapy Utilization and Costs to a Medicaid Managed Care Plan.
    Corelli RL; Tu TG; Lee KJ; Dinh D; Gericke KR; Hudmon KS
    Pharmacoecon Open; 2021 Dec; 5(4):649-653. PubMed ID: 34109569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Utilization, Spending, and Prices of Smoking-Cessation Medications in Medicaid Programs: 25 Years Empirical Data Analysis, 1991-2015.
    Yue X; Guo JJ; Wigle PR
    Am Health Drug Benefits; 2018 Sep; 11(6):275-285. PubMed ID: 30464795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare Payers.
    Baker CL; Ferrufino CP; Bruno M; Kowal S
    Adv Ther; 2017 Jan; 34(1):156-170. PubMed ID: 27888437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012.
    Jarlenski M; Hyon Baik S; Zhang Y
    Am J Prev Med; 2016 Sep; 51(3):301-8. PubMed ID: 27036506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM; Lyseng-Williamson KA
    Pharmacoeconomics; 2010; 28(3):231-54. PubMed ID: 20108995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-benefit analysis of smoking cessation prescription coverage from a US payer perspective.
    Baker CL; Ding Y; Ferrufino CP; Kowal S; Tan J; Subedi P
    Clinicoecon Outcomes Res; 2018; 10():359-370. PubMed ID: 30038510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General practitioner prescribing of single and combination nicotine replacement therapy in the UK: a retrospective database study.
    Johnson M; Anderson P; Lockhart I
    BMC Fam Pract; 2014 Mar; 15():47. PubMed ID: 24645823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
    Bailey SR; Crew EE; Riske EC; Ammerman S; Robinson TN; Killen JD
    Paediatr Drugs; 2012 Apr; 14(2):91-108. PubMed ID: 22248234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions.
    Getsios D; Marton JP; Revankar N; Ward AJ; Willke RJ; Rublee D; Ishak KJ; Xenakis JG
    Pharmacoeconomics; 2013 Sep; 31(9):767-80. PubMed ID: 23821436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of smoking cessation medication benefits among medicaid fee-for-service enrollees 1999-2008.
    Kahende J; Malarcher A; England L; Zhang L; Mowery P; Xu X; Sevilimedu V; Rolle I
    PLoS One; 2017; 12(2):e0170381. PubMed ID: 28207744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
    Howard P; Knight C; Boler A; Baker C
    Pharmacoeconomics; 2008; 26(6):497-511. PubMed ID: 18489200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of real-world administration of tobacco pharmacotherapy in the United States Veterans Health Administration.
    Barnett PG; Ignacio RV; Kim HM; Geraci MC; Essenmacher CA; Hall SV; Sherman SE; Duffy SA
    Addiction; 2019 Aug; 114(8):1436-1445. PubMed ID: 30924195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which drug to be used in smoking cessation?
    Tønnesen P
    Pol Arch Med Wewn; 2008 Jun; 118(6):373-6. PubMed ID: 18619194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
    Annemans L; Nackaerts K; Bartsch P; Prignot J; Marbaix S
    Clin Drug Investig; 2009; 29(10):655-65. PubMed ID: 19715382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M; Welsing P; Rutten-van Mölken MP
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.